Evidence map›Paper›PMID 35840685›Full record

ArticleNature2022

Author Correction: Tryptophan depletion results in tryptophan-to-phenylalanine substitutants.

Abhijeet Pataskar, Julien Champagne, Remco Nagel, Juliana Kenski, Maarja Laos, Justine Michaux, Hui Song Pak, Onno B Bleijerveld, Kelly Mordente, Jasmine Montenegro Navarro and 14 more

Abstract readPublished Erratum
In one paragraph

Article in Nature, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors.

Abhijeet Pataskar *Division of Oncogenomics, Oncode institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Julien Champagne *Division of Oncogenomics, Oncode institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0001-8460-858X
Remco Nagel *Division of Oncogenomics, Oncode institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Juliana KenskiDivision of Molecular Oncology and Immunology, Oncode institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Maarja LaosDepartment of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway.
Justine MichauxLausanne Branch, Ludwig Institute for Cancer Research, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.
Hui Song PakLausanne Branch, Ludwig Institute for Cancer Research, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.
Onno B BleijerveldNKI Proteomics facility, The Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0002-9395-2347
Kelly MordenteDivision of Oncogenomics, Oncode institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Jasmine Montenegro NavarroDivision of Oncogenomics, Oncode institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Naomi BlommaertDivision of Oncogenomics, Oncode institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Morten M NielsenDepartment of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway.
Domenica LovecchioDivision of Oncogenomics, Oncode institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0002-6297-8384
Everett StoneDepartment of Molecular Biosciences, University of Texas, Austin, TX, USA.
George GeorgiouDepartment of Molecular Biosciences, University of Texas, Austin, TX, USA.ORCID http://orcid.org/0000-0002-8823-3073
Mark C de GooijerDivision of Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0002-2812-991X
Olaf van TellingenDivision of Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0002-1037-6269
Maarten AltelaarNKI Proteomics facility, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Robbie P JoostenDivision of Biochemistry, The Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0002-2323-2686
Anastassis PerrakisDivision of Biochemistry, The Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0002-1151-6227
Johanna OlweusDepartment of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway.ORCID http://orcid.org/0000-0002-1898-3100
Michal Bassani-SternbergLausanne Branch, Ludwig Institute for Cancer Research, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.ORCID http://orcid.org/0000-0002-1934-954X
Daniel S PeeperDivision of Molecular Oncology and Immunology, Oncode institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0003-1293-3177
Reuven AgamiDivision of Oncogenomics, Oncode institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands. r.agami@nki.nl.ORCID http://orcid.org/0000-0002-2848-2473

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID35840685
PMCPMC9365688

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.